Author name: Don Mccaughey

VANCOUVER, BC, /PRNewswire/ — Bold Therapeutics Inc., a clinical-stage biopharmaceutical company pioneering novel oncology treatments, today announced that its Sr. Director of Preclinical Development, Mark Bazett, PhD, is presenting a late-breaking poster on BOLD-100’s potent neuroprotective properties later today at the American Association for Cancer Research (AACR) Annual Meeting 2025. Session:           Late-Breaking Research: Experimental and Molecular Therapeutics 4 Neuropathy Rates from BOLD-100-001 vs. Historical Controls Bold Therapeutics’ Data in a Model of Cold Allodynia Date & Time:   April 30, 2025, from 9:00 AM to 12:00 PM Location:         Poster Section 51, Poster Board #14 Poster Code:   #LB432 Poster Title:    “Clinical-stage anticancer agent BOLD-100 demonstrates protective effects against oxaliplatin-induced peripheral neuropathy in an in-vivo rat model” Addressing a Critical Unmet Need: Oxaliplatin-Induced Peripheral Neuropathy In Bold Therapeutics’ global Phase 1b/2a trial (BOLD-100-001, NCT04421820), patients with advanced gastrointestinal cancers — including colorectal (mCRC), gastric (GC), biliary tract (BTC), and pancreatic cancer (PDAC) — were treated with BOLD-100 in combination with FOLFOX (5-fluorouracil, oxaliplatin, leucovorin). Across 109 patients in six treatment arms, the study showed encouraging efficacy data, which was previously presented at ESMO GI and ASCO in 2024. A surprising finding from this trial was a profound reduction in both the frequency and severity of oxaliplatin-induced peripheral neuropathy (OIPN), a relatively common and debilitating side effect of chemotherapy. In each patient cohort, rates of neuropathy were dramatically lower than those typically seen in historical benchmarks for FOLFOX alone: These results were supported by feedback from trial investigators, many of whom noted the unexpectedly low incidence of neuropathy in their patients treated with BOLD-100 — particularly those who were heavily pretreated and/or receiving FOLFOX again where one would expect both a high incidence and severity of neuropathy. To better understand this effect, Bold Therapeutics developed a preclinical rat model of cold allodynia, a common symptom of OIPN. Rats were treated with either high or low doses of oxaliplatin and then given BOLD-100 every three days for 17 days. The results confirmed the clinical findings: rats receiving BOLD-100 showed significantly less neuropathic pain. Once treatment with BOLD-100 stopped, neuropathy symptoms rapidly returned, further supporting its protective effect. These findings prompted further efforts to elucidate BOLD-100’s neuroprotective mechanism and investigation into whether BOLD-100 can prevent or reduce neuropathy from other neuropathy-inducing agents, such as the taxanes. BOLD-100’s unique ability to both directly impact cancer while simultaneously preventing or reducing OIPN could redefine first-line treatment by helping patients: Improve overall outcomes through direct anti-cancer activity and completing full chemotherapy cycles. Stay on therapy longer without dose reductions or early discontinuation. Experience less pain, tingling, and sensory issues that impact daily life. Avoid long-term nerve damage that can persist long after treatment ends. Ongoing Clinical Study and Future Outlook Bold Therapeutics is currently enrolling FOLFOX-naïve second-line mCRC patients in a multinational randomized clinical study comparing FOLFOX vs. FOLFOX + BOLD-100 in various efficacy, safety, and quality-of-life endpoints. Bold Therapeutics anticipates this trial will further demonstrate BOLD-100’s potential as a transformative therapy in early-line colorectal cancer, biliary tract cancer and other solid tumor indications. Bold Therapeutics invites investors, strategic partners, clinical investigators and key opinion leaders to connect with the team at AACR to discuss these latest findings, the company’s ongoing clinical development plans, and potential strategic collaborations. For more information about Bold Therapeutics, please visit: https://www.bold-therapeutics.com/ or contact us at the address below. About Bold Therapeutics Inc. Bold Therapeutics Inc. is a clinical-stage biopharmaceutical company advancing innovative oncology treatments. The company’s lead asset, BOLD-100, is a first-in-class selective GRP78 inhibitor that results in stress-induced apoptosis. With its novel mechanism-of-action and demonstrated clinical potential, BOLD-100 is actively being developed across multiple oncology indications. CONTACT: E. Russell McAllister, CEO+1 (604) [email protected] SOURCE Bold Therapeutics Inc.

Vancouver, BC  – Bold Therapeutics Inc., a clinical-stage biopharmaceutical company pioneering novel oncology treatments, today announced that its Sr. Director of Preclinical Development, Mark Bazett, PhD, will be presenting a late-breaking poster on BOLD-100’s potent neuroprotective properties at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25–30, 2025, in Chicago, Illinois. Mark Bazett will be joined by Jim Pankovich, EVP Clinical Development, and Ashish Kumar, PhD, Sr. Scientist. Session: Late-Breaking Research: Experimental and Molecular Therapeutics 4 Date & Time: April 30, 2025, from 9:00 AM to 12:00 PM Location: Poster Section 51, Poster Board #14 Poster Code: #LB432 Poster Title: “Clinical-stage anticancer agent BOLD-100 demonstrates protective effects against oxaliplatin-induced peripheral neuropathy in an in-vivo rat model” Building on Bold Therapeutics’ Phase 2 data showing both direct anticancer activity and a dramatic reduction in the incidence and severity of OIPN in patients treated with BOLD-100, these findings pave the way for a pivotal Phase 3 clinical trial and an accelerated pathway to approval in first-line metastatic colorectal cancer (mCRC), with BOLD-100 potentially treating up to 85% of first-line mCRC patients. According to an independent analysis conducted by a leading U.S. life science investment bank that was supported by extensive physician and payer interviews, this expanded clinical positioning results in a potential multibillion-dollar commercial opportunity starting in 2030 — a figure that underscores BOLD-100’s broad market potential and the urgent unmet medical needs that BOLD-100 could potentially address. Addressing a Critical Unmet Need: Oxaliplatin-Induced Peripheral Neuropathy Peripheral neuropathy is one of the most significant and debilitating toxicities of oxaliplatin, the gold-standard chemotherapy used in treating metastatic colorectal cancer. Up to 85% of patients receiving oxaliplatin develop some degree of neuropathy, with 30-50% experiencing persistent, chronic symptoms that can severely impact their quality-of-life. This condition often manifests as pain, tingling, numbness, and extreme cold sensitivity, affecting the hands, feet, and oral cavity — compromising a patient’s ability to perform routine daily activities. For many patients, peripheral neuropathy becomes the primary reason for dose reductions, treatment interruptions, and/or early discontinuation of oxaliplatin-based therapy, directly impacting therapeutic outcomes and survival benefits. With no approved treatments to prevent or reverse OIPN, oncologists must often make difficult trade-offs between maintaining treatment efficacy and preserving a patient’s long-term quality of life. For this reason, some physicians prefer to give FOLFIRI in the first-line setting, even though it is less effective than FOLFOX. BOLD-100’s ability to increase anticancer efficacy in combination with FOLFOX while simultaneously mitigating OIPN represents a significant therapeutic breakthrough, potentially allowing patients to: ▪ Complete full treatment cycles without requiring dose modifications or early discontinuation. ▪ Maintain better functional independence and quality of life by reducing pain and sensory impairments. ▪ Avoid long-term, irreversible nerve damage, which can persist for years after chemotherapy ends. ▪ Enhance overall treatment adherence and clinical outcomes by ensuring patients receive the full therapeutic benefit of first-line chemotherapy. Ongoing Clinical Study and Future Outlook Bold Therapeutics is currently enrolling FOLFOX-naïve second-line mCRC patients in a multinational randomized clinical study comparing FOLFOX vs. FOLFOX + BOLD-100 in various efficacy, safety, and quality-of-life endpoints. Bold Therapeutics anticipates this trial will further demonstrate BOLD-100’s potential as a transformative therapy in early-line colorectal cancer, biliary tract cancer and other solid tumor indications. Bold Therapeutics invites investors, strategic partners, clinical investigators and key opinion leaders to connect with the team at AACR to discuss these latest findings, the company’s ongoing clinical development plans, and potential strategic collaborations. For more information about Bold Therapeutics or to schedule a meeting at AACR, please visit: https://www.bold-therapeutics.com/ or contact us at the address below. Source: Bold Therapeutics Inc. Contact: E. Russell McAllister, CEO [email protected] About Bold Therapeutics Inc. Bold Therapeutics Inc. is a clinical-stage biopharmaceutical company advancing innovative oncology treatments. The company’s lead asset, BOLD-100, is a first-in-class selective GRP78 inhibitor that results in stress-induced apoptosis. With its novel mechanism-of-action and demonstrated clinical potential, BOLD-100 is actively being developed across multiple oncology indications.

CHARLOTTE, NC  – Gaston Capital, LLC, a Charlotte-based private equity firm, announces the promotion of Kyle Radavich to Senior Associate. In this role, Radavich will take on expanded responsibilities in deal sourcing, due diligence, and portfolio company management, while working with the firm’s leadership team to advance investment strategy and execution. Glenn Walthall, Managing Partner of Gaston Capital, commented on the promotion: “Kyle has become a valuable member of our team since joining us last year. His strong analytical capabilities, solid work ethic, and strategic thinking have enhanced our investment process. We’re pleased to recognize his contributions with this promotion and look forward to his continued impact on our firm.” Radavich joined Gaston Capital in 2024 as an Associate after a successful tenure at Five Points Capital, where he specialized in credit investments. He holds a BBA in Finance from the University of Wisconsin Oshkosh, where he distinguished himself as both a scholar and athlete on the football team, graduating in 2020. “I appreciate the opportunity to take on greater responsibilities at Gaston Capital,” said Radavich. “I look forward to continuing to work with our team and portfolio companies to create value for our investors and stakeholders.” Gaston Capital invests in Lower Middle Market companies across healthcare, financial services, business services, light industrial, and SaaS sectors. The firm utilizes emerging technologies to support growth and create value. For more information, please visit GastonCapital.com or contact: Don McCaughey Gaston Capital, LLC [email protected]  

VANCOUVER, BC, June 24, 2024 /PRNewswire/ — Bold Therapeutics, a clinical-stage metallotherapeutics company, has been invited to speak at the 2024 ‘Metals in Medicine’ GRC held in Andover, New Hampshire between June 23 to 28, 2024. The conference program, Fostering Collaborations to Diagnose and Treat Diseases with Metal-Based Agents, features a variety of global speakers and academic experts targeting the most recent advancements in the field of metallotherapeutics to treat infectious diseases and cancer. Mark Bazett, PhD, Sr Director of Preclinical Development at Bold Therapeutics, presented on Monday, June 24th, in the session titled: Clinical Advances for Metals in Medicine. Bazett’s talk is titled, Clinical Development of BOLD-100, a Ruthenium-Based Therapeutic Currently in Phase 2 Studies for the Treatment of Advanced Gastrointestinal Cancers. Dr. Bazett presented positive Phase 2 clinical results of BOLD-100 in colorectal, biliary tract, and gastric cancers, as well as sharing updates on Bold Therapeutics’ unique novel metallotherapeutic screening program and development strategy. Shane Harrypersad, PhD, Sr Scientist, CMC is also representing Bold Therapeutics at the Metals in Medicine conference. “Following the announcement of strongly positive Phase 2 results at the 2024 ASCO and ASCO GI Annual Meetings earlier this year, Bold Therapeutics’ BOLD-100 is now the most advanced novel metallotherapeutic in development,” stated Dr. Bazett. “The ‘Metals in Medicine’ conference represents an excellent opportunity for industry leader Bold Therapeutics to strengthen our existing academic collaborations as well as identify compelling new collaborations and potential metallotherapeutic development candidates from the top labs globally.” In addition to presenting at the conference, Bold Therapeutics will be meeting with academic experts and key opinion leaders in the metallotherapeutic space. Yasmin Borutzki, BSc. MSc., a graduate student in the Meier-Menches Lab at University of Vienna, a close collaborator of Bold Therapeutics, presented a poster on translational research into BOLD-100 entitled: Of Mice and Men: Reverse Translation Investigation of BOLD-100’s Mechanism-of-Action. For more information about Bold Therapeutics, please visit: https://www.bold-therapeutics.com/  

VANCOUVER, BC, June 3, 2024 /PRNewswire/ — Bold Therapeutics, the world leader in the development of novel metallotherapeutics, announced positive Phase 2 safety and efficacy results for the company’s lead asset BOLD-100 in the treatment of advanced metastatic biliary tract cancer (BTC) and gastric cancer (GC) at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, IL. This follows positive Phase 2 results in the treatment of advanced colorectal cancer presented at the 2024 ASCO Gastrointestinal Cancers Symposium in January. BTC and GC data from Bold Therapeutics’ ongoing multinational Phase 2 clinical trial (NCT04421820) of BOLD-100 in combination with standard-of-care FOLFOX in the treatment of patients with advanced gastrointestinal cancers at sites in Canada, the United States, Ireland, and South Koreawas presented as Abstract #4115 (Poster Board #95) “A Phase 2 Study of BOLD-100 in combination with FOLFOX chemotherapy in patients with pretreated advanced biliary tract cancer: efficacy and safety analysis” and Abstract #4059 (Poster Board #39) “A Phase 2 Study of BOLD-100 in combination with FOLFOX chemotherapy in patients with advanced gastric cancer: efficacy and safety analysis”, respectively, in the Gastrointestinal Cancer – Gastroesophageal, Pancreatic, and Hepatobiliary session on June 1, 2024, from 1:30 – 4:30PM CDT. BTC Efficacy and Safety: 18 out of 22 patients treated were eligible for efficacy evaluation; Median progression-free survival (PFS) of 6.0 months [95% CI: 3.8 – 10.0] and median OS of 7.3 months [95% CI: 4.5 – 13.0], which compares extremely favorably with standard-of-care outcomes; One patient (n=1) achieving a partial response (PR) for an objective response rate (ORR) of 6% [95% CI: 1.0, 23.0], fourteen (n=14) patients with stable disease (SD), and disease control rate (DCR) of 83% [95% CI: 62.0, 95.0]; Patients received a median of 4 cycles (range: 1 – 41) of therapy; and For all treated patients (n=21), 21 had ≥ 1 TRAEs, most commonly neutrophil count decrease (n=10, 46%), nausea (n=8, 36%), fatigue (n=7, 32%), peripheral-sensory neuropathy (n=6, 27%), and pyrexia (n=6, 27%). GC Efficacy and Safety: 18 out of 21 patients treated were eligible for efficacy evaluation; Median progression-free survival (PFS) of 4.2 months [95% CI: 2.8 – 7.1] and median OS of 7.9 months [95% CI: 4.8 – 15.0], which compares extremely favorably with standard-of-care outcomes; Two patients (n=2) achieved a partial response (PR) for an objective response rate (ORR) of 11% [95% CI: 2.0, 31.0], eleven (n=11) patients with stable disease (SD), and disease control rate (DCR) of 72% [95% CI: 49.0, 89.0]; Patients received a median of 6 cycles (range: 1 – 27) of therapy; and For all treated patients (n=21), 19 patients had ≥ 1 TRAEs, most commonly neutrophil count decrease (n=7, 33%), nausea (n=6, 29%), and peripheral-sensory neuropathy (n=4, 19%), with most AEs being grade 1-2. “Driven by our dedicated and talented employees and supported by generous grants and subsidies from the government of Canada, BOLD-100 continues to exceed expectations,” added E. Russell McAllister, CEO. “On top of the robustly positive Phase 2 clinical data presented at both ASCO and ASCO GI, Bold Therapeutics expects to announce intriguing nonclinical data later this year, specifically biomarker data that we think will generate significant excitement amongst both clinicians and scientists as we disrupt commonly held perceptions about how to safely and effectively treat some of the most difficult-to-treat solid tumor indications where existing therapies are largely ineffective.” Later this month, Bold Therapeutics expects to begin enrolling patients into a multinational Phase 2 randomized clinical trial comparing two different doses of BOLD-100 in combination with standard-of-care FOLFOX against standard-of-care FOLFOX in patients with second-line FOLFOX-naïve colorectal cancer. Based on prior results, we expect to see significant improvements in both safety and efficacy outcomes. In addition, Bold Therapeutics is currently manufacturing drug product to support a pivotal Phase 3 trial in advanced colorectal cancer. For more information, please visit the Company’s website at https://www.bold-therapeutics.com/ Source: Bold Therapeutics Inc.Contact: E. Russell McAllister, CEO+1 (604) [email protected]

Gaston Capital, LLC., a Charlotte based venture capital firm founded in 2006, is pleased to announce the addition of Kyle Radavich as Associate.  Radavich will be responsible for supporting the firm’s investment activities, where he will work closely with the partners as an integral part of the investment team. The announcement was made April 15th by Glenn Walthall, newly appointed Managing Partner, and longtime CIO of Gaston Capital. “Kyle Radavich will make a great addition to our small and growing team. His proven skills and analytic talent will greatly enhance our ability to identify target companies and execute our overall strategy”. Radavich joined Gaston Capital from Five Points Capital, where he focused on the firm’s credit strategy. He is a 2020 graduate of the University of Wisconsin Oshkosh, where he earned a BBA in Finance and played football as a D3 scholar/athlete.  Radavich states, “Gaston Capital’s thoughtful approach, strong track record, and proven commitment to the venture capital market is a perfect fit for my background and analytical skill set.  I’m excited to contribute to the future success of this team”. Gaston Capital focuses on Lower Middle Market companies located in the United States with an emphasis on healthcare, financial services, business services, light industrial and SaaS.  The firm pays particular attention to how emerging technologies might transform traditional businesses for breakout strategic advantage.

Gaston Capital Founder Michael (Mick) McMahan recently announced the promotion of Glenn Walthall to the position of Managing Partner, following his accomplishments as Chief Investment Officer since 2015.  Now entering his tenth year with the firm, Walthall has helped oversee the success of Gaston Capital and its continued evolution.  “As Managing Partner, Glenn will continue to bring best practices to all aspects of the company, as well as explore strategic opportunities to support the firm’s continued growth”, says McMahan, who will continue in the role of Founding Partner. A graduate of Virginia Tech, with a BS in Management and an MBA from Pamplin College of Business, Walthall’s investment banking career spans three decades in the Charlotte area, with significant tenures at First Union and Bank of America as well several banking advisory firms. Walthall has been instrumental in all aspects of Gaston Capital’s strategy and day to day operations and currently sits on the boards of several of the firm’s portfolio companies.  “My goal for Gaston Capital is to expand our investor base in a thoughtful way that allows us to continue to deliver superior returns in the industries where we have demonstrated consistent value creation”, says Walthall. Gaston Capital was founded in 2006 with a simple objective of finding and supporting companies that possess great potential. Our founder believed that innovation and hard work alone aren’t enough to make companies great. Truly great companies also need strong leadership, a disciplined approach to growth, and unwavering support from its financial sponsors. Gaston Capital seeks to invest in companies that are driven to be great. The firm makes meaningful minority investments focused on healthcare, financial services, business services, light industrial, and SaaS companies located in the United States.

Next-Generation Monitoring System Elevates Safety Standards in Food Service and Healthcare CHARLOTTE, NC / ACCESSWIRE / March 7, 2024 / Enviro-Master, the nation’s premier health and safety franchise company, announces the launch of its innovative Enviro-Safe app, a cutting-edge technology tool designed to revolutionize temperature monitoring and hygiene practices in food service, healthcare, and other industries requiring stringent safety standards. The Enviro-Safe app includes a cold storage monitoring system that ensures optimal temperature conditions for refrigerators and freezers, crucial for businesses handling perishable goods. With its advanced sensor technology, the app provides real-time alerts and data logging to prevent spoilage and ensure compliance with health regulations. “The Enviro-Safe app’s temperature monitoring system is a game-changer for the industry,” says Dave Goodwin, Director of Technology Innovation at Enviro-Master. “Its ability to monitor conditions in real-time and provide immediate alerts is invaluable for businesses looking to maintain the highest standards of safety and quality.” Benefits of Using the Enviro-Safe App Health Code Compliance: By maintaining optimal temperature conditions and enabling immediate corrective actions, the app helps facilities avoid violations of health codes, which can result in fines or closures. Sensor Capabilities: The system employs sensors capable of monitoring a wide range of temperatures. These include standard refrigerator and freezer temperatures, as well as ultra-low freezer temperatures reaching down to -80 °C. Such capability ensures that even the most sensitive products, requiring stringent temperature controls, are adequately monitored. Data Logging: The sensors function as data loggers, recording temperature data to provide evidence that temperatures have remained within the safe and required ranges. This feature is invaluable for compliance and safety audits, offering proof of proper storage conditions over time. Waste Reduction: The app’s alert system helps prevent spoilage of perishable goods due to temperature fluctuations. This not only reduces waste but also contributes to cost savings for the business. Prevention of Equipment Misuse: The app can help identify instances where freezer or cooler doors are inadvertently left open, a common issue that can lead to temperature spikes and increased energy consumption. By addressing this, businesses can improve energy efficiency and prevent spoilage. “Ensuring the integrity of perishable goods and sensitive medications in food service and healthcare facilities is as much about compliance as it is public safety,” adds Goodwin. “For healthcare facilities, where the proper storage of medications and vaccines is non-negotiable, the app provides peace of mind, ensuring that these critical items are maintained at the exact temperatures required for their efficacy.” Innovative Paper Product Monitoring Beyond temperature monitoring, Enviro-Master’s new line of paper towel and toilet tissue dispensers are specifically designed to accommodate sensors that connect to the Enviro-Safe app. This integration ensures seamless monitoring of paper product levels, signaling facility managers or staff when a refill is necessary. Improved Hygiene: Ensures that paper towels and toilet tissue are always available and helps maintain cleanliness and user satisfaction in restrooms. Efficiency: Automated alerts reduce the need for manual checks, allowing staff to focus on other tasks until a refill is needed. Cost Management: By monitoring usage and refilling only when necessary, facilities can better manage supply costs and reduce waste. A Commitment to Innovation and Excellence Since its inception in 2009, businesses across North America have entrusted Enviro-Master with their health and safety needs. The company’s comprehensive suite of services includes the commercial restroom cleaning program, commercial tile and grout cleaning, drain treatment, and the unique Virus Vaporizer™ electrostatic spraying protection service. Enviro-Master also offers an exclusive line of restroom paper dispensers, along with paper restocking and hand sanitizer services. “At Enviro-Master, we pride ourselves on being pioneers in the industry, consistently pushing the boundaries of what’s possible in hygiene and safety solutions. The Enviro-Safe app sets us apart as a technology-forward company that leads rather than follows,” states Tod Bierling, CEO of Enviro-Master Services. “By integrating advanced monitoring capabilities into our services, we continue to redefine standards and exceed expectations, ensuring our clients are always a step ahead.” The launch of the Enviro-Safe app underscores Enviro-Master’s commitment to leveraging technology to improve health and safety standards in commercial environments and offering businesses across various sectors the tools they need to ensure a safe, efficient, and compliant operation. To learn more about the Enviro-Safe app, contact Dave Goodwin at [email protected].   About Enviro-Master Enviro-Master is a leading health and safety franchise company specializing in comprehensive solutions for businesses nationwide. With a commitment to cleanliness, hygiene, and environmental sustainability, Enviro-Master delivers a range of services, including commercial power washing, commercial window cleaning, and commercial restroom hygiene, to promote safe and healthy business environments. To learn more about franchising opportunities with Enviro-Master, visit https://franchise.enviro-master.com/. Media Contact: Tammy Delgado [email protected] 919-459-7147 SOURCE: Enviro-Master

The multifaceted alliance underscores the two companies’ shared commitment to innovation and market expansion. Logan, UT and Santa Monica, CA—February 21, 2024—Freemotion Fitness, renowned for its cutting-edge fitness equipment, and Aktiv Solutions, the leading expert in functional fitness facility supply and design, have entered into a strategic partnership. The multifaceted alliance underscores the two companies’ shared commitment to innovation and market expansion. The partnership will also extend to a range of each of the companies’ distribution networks, enabling access to the entire suite of Freemotion and Aktiv products. As a key facet of the collaboration, Freemotion Fitness will now take part in the global representation of Aktiv’s specialty equipment and accessory-based solutions in tandem with Aktiv’s unique facility design capabilities. The agreement is a testament to the trust in Freemotion’s global market reach and influence. Reciprocally, Aktiv Solutions will extend its current representation of the extensive range of Freemotion equipment, broadening the collective company’s impact and global customer reach. Mark Watterson, CEO of Freemotion Fitness, said the partnership marks a significant milestone for Freemotion. “By joining forces, we are poised to unlock new markets and propel our growth trajectory,” Watterson said. “Together, we are stronger and better equipped to provide unparalleled fitness solutions for an ever-evolving industry.” The synergy not only facilitates the exchange of cutting-edge fitness solutions but also opens doors to collaborative ventures at industry events and shows. Aktiv will debut the recent launch of its Smith 3D Trainer™ among its portfolio of industry-leading training tools within Freemotion’s exhibition at this year’s IHRSA Global Trade show in Los Angeles on March 7th and 8th. By synergizing their strengths, Freemotion and Aktiv Solutions aim to redefine the fitness equipment landscape, offering customers an unparalleled range of products and services. “At Aktiv, we believe that successful fitness facilities offer more than simple function and utility – they deliver experiences,” said Bryan Green, Founder and CEO of Aktiv Solutions. “As operators get more creative, movement-based modalities will continue to dominate the exercise floor. Our partnership with Freemotion strengthens our ability to offer the most comprehensive and impactful solutions for commercial clients everywhere.” Emphasizing the strategic significance of the deal, Watterson added: “This partnership is not just about products; it’s about creating a collective impact for our clients. We know the Aktiv team well and believe in the power of collaboration to drive innovation and elevate the fitness experience for our customers.” As the fitness industry undergoes rapid transformation, the strategic partnership serves to position both Freemotion and Aktiv Solutions at the forefront, ready to meet evolving market demands. About Aktiv Solutions At Aktiv, we Design The Exercise Experience®. Aktiv’s end-to-end solutions equip both commercial and residential fitness spaces with premium products and digital guidance powering today’s most sought-after workouts. GYM RAX® is the world’s leading fitness rigging solution for modular storage and equipment suspension. Aktiv harnesses the power of movement-based modalities with the technical expertise of functional design. Our mission is to establish safe and engaging health clubs, studios, hotel gyms, corporate fitness centers, multi-family amenities, and beyond, while our clients deliver inspirational exercise experiences. For more information, visit aktivsolutions.com